These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. A case report of osteoarthritis associated with hereditary transthyretin amyloidosis ATTRV30M. Anan I; Bång J; Lundgren HE; Wixner J; Westermark P Amyloid; 2019; 26(sup1):29-30. PubMed ID: 31343355 [No Abstract] [Full Text] [Related]
24. Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan. Yamashita T; Ueda M; Misumi Y; Masuda T; Nomura T; Tasaki M; Takamatsu K; Sasada K; Obayashi K; Matsui H; Ando Y J Neurol; 2018 Jan; 265(1):134-140. PubMed ID: 29177547 [TBL] [Abstract][Full Text] [Related]
25. Cardiac Involvement in a Patient Cohort With Val30Met Mutation Transthyretin Amyloidosis. Ripoll-Vera T; Buades J; Cisneros E; Gómez Y; Núñez J; Raya M Rev Esp Cardiol (Engl Ed); 2019 Jan; 72(1):92-94. PubMed ID: 29223374 [No Abstract] [Full Text] [Related]
26. Clinical and pathological findings in familial amyloid polyneuropathy caused by a transthyretin E61K mutation. Murakami T; Nishimura H; Nagai T; Hemmi S; Kutoku Y; Ohsawa Y; Sunada Y J Neurol Sci; 2017 Oct; 381():55-58. PubMed ID: 28991715 [TBL] [Abstract][Full Text] [Related]
27. A case of transthyretin amyloidosis with myopathy, neuropathy, and cardiomyopathy resulting from an exceedingly rare mutation transthyretin Ala120Ser (c.418G > T, p.Ala140Ser). Patel K; Tagoe C; Bieri P; Weidenheim K; Tauras JM Amyloid; 2018 Sep; 25(3):211-212. PubMed ID: 30039724 [No Abstract] [Full Text] [Related]
28. Parent-of-origin effect in transthyretin related amyloid polyneuropathy. Bonaïti B; Alarcon F; Bonaïti-Pellié C; Planté-Bordeneuve V Amyloid; 2009; 16(3):149-50. PubMed ID: 19626480 [No Abstract] [Full Text] [Related]
29. Hereditary ATTR amyloidosis: a single-institution experience with 266 patients. Swiecicki PL; Zhen DB; Mauermann ML; Kyle RA; Zeldenrust SR; Grogan M; Dispenzieri A; Gertz MA Amyloid; 2015; 22(2):123-31. PubMed ID: 26017327 [TBL] [Abstract][Full Text] [Related]
30. An aggressive form of familial amyloid polyneuropathy caused by a Glu54Gly mutation in the transthyretin gene. Kim HS; Kim SM; Kang SW; Jung SC; Lee KS; Kim TS; Choi YC Eur J Neurol; 2005 Aug; 12(8):657-9. PubMed ID: 16053476 [TBL] [Abstract][Full Text] [Related]
31. Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy. Koike H; Ando Y; Ueda M; Kawagashira Y; Iijima M; Fujitake J; Hayashi M; Yamamoto M; Mukai E; Nakamura T; Katsuno M; Hattori N; Sobue G J Neurol Sci; 2009 Dec; 287(1-2):178-84. PubMed ID: 19709674 [TBL] [Abstract][Full Text] [Related]
32. Homozygosity for the V122I mutation in transthyretin is associated with earlier onset of cardiac amyloidosis in the African American population in the seventh decade of life. Reddi HV; Jenkins S; Theis J; Thomas BC; Connors LH; Van Rhee F; Highsmith WE J Mol Diagn; 2014 Jan; 16(1):68-74. PubMed ID: 24184229 [TBL] [Abstract][Full Text] [Related]
33. Clinical manifestations in hereditary amyloidosis with the variant Glu54Gln transthyretin. Jercan A; Badelita S; Draghici M; Stoica E; Iacob S; Coriu D Amyloid; 2019; 26(sup1):31-32. PubMed ID: 31343281 [No Abstract] [Full Text] [Related]
34. The Swedish open-label diflunisal trial (DFNS01) on hereditary transthyretin amyloidosis and the impact of amyloid fibril composition. Wixner J; Westermark P; Ihse E; Pilebro B; Lundgren HE; Anan I Amyloid; 2019; 26(sup1):39-40. PubMed ID: 31343354 [No Abstract] [Full Text] [Related]
35. Carpal tunnel syndrome as an initial manifestation in a case of transthyretin-related familial amyloid polyneuropathy with a novel A120T mutation. Koyama S; Kawanami T; Kurokawa K; Tanji H; Iseki C; Arawaka S; Wada M; Kato T Clin Neurol Neurosurg; 2012 Jul; 114(6):707-9. PubMed ID: 22209138 [No Abstract] [Full Text] [Related]
36. Dominant cardiac type of familial amyloidotic polyneuropathy associated with a novel transthyretin variant Thr59Arg. Obayashi K; Misumi Y; Watanabe T; Ando T; Akagami T; Tasaki M; Shinriki S; Ueda M; Yamashita T; Hirotani S; Ando Y Muscle Nerve; 2013 Nov; 48(5):839-41. PubMed ID: 23836350 [No Abstract] [Full Text] [Related]
37. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings. Maia LF; Magalhães R; Freitas J; Taipa R; Pires MM; Osório H; Dias D; Pessegueiro H; Correia M; Coelho T J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):159-67. PubMed ID: 25091367 [TBL] [Abstract][Full Text] [Related]
38. Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis. Yang J Expert Rev Clin Pharmacol; 2019 Feb; 12(2):95-99. PubMed ID: 30644768 [TBL] [Abstract][Full Text] [Related]
40. Misdiagnosis in late versus early onset hATTR amyloidosis patients: experience from a reference centre. Falcão de Campos C; Parreira S; Conceição I Amyloid; 2019; 26(sup1):37-38. PubMed ID: 31343293 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]